Rockville, Maryland — October 1, 2026 — The cell and gene therapy clinical trials market is expected to expand from USD 14.3 billion in 2026 to USD 61.5 billion by 2036, advancing at a 15.7% CAGR over the forecast period. The market is being shaped by increasing clinical development activity, rising investment in advanced therapies, expanding healthcare infrastructure, and growing requirements for specialized trial services supporting complex cell and gene therapy programs.
Get detailed market forecasts, competitive benchmarking, and pricing trends:
The development of innovative treatments for cancer, rare diseases, genetic disorders, and other serious conditions remains a major factor supporting clinical trial activity. As pharmaceutical and biotechnology companies expand their pipelines, demand is increasing for clinical research organizations, specialized laboratory services, regulatory expertise, patient recruitment capabilities, and other infrastructure required to conduct advanced therapy trials. The report also highlights the importance of regulatory evolution and institutional capabilities in supporting wider adoption of these therapies.
Gene Therapy Trials Maintain a Leading Position
Gene Therapy Trials account for 38.6% of the market in 2026, making this the leading segment by trial type. Continued investment in gene-based therapeutic approaches, together with established clinical development practices and regulatory progress, supports the segment’s position. The growing number of candidates entering clinical development is also increasing demand for specialized trial management and supporting services.
By trial phase, Early Phase Trials represent 42.1% of the market in 2026. These trials remain central to evaluating safety, tolerability, dosing, and initial therapeutic responses before candidates progress toward later-stage development. Oncology is another prominent area, accounting for 51.4% of therapeutic-area demand, reflecting substantial clinical development activity involving advanced therapies for cancer treatment.
China, Japan and Germany Show Strong Growth
China is projected to record a 16.1% CAGR through 2036, the highest growth rate among the countries highlighted in the title. Increasing investment in healthcare infrastructure, expanding clinical research capabilities, and rising demand for advanced therapeutic approaches are contributing to the country’s market development. China’s growing biotechnology ecosystem also provides a broader base for clinical development activities.
Japan is forecast to expand at a 15.3% CAGR during the same period. The country’s established healthcare system, regulatory developments, and increasing interest in advanced therapeutic technologies support continued clinical trial activity. Growing attention toward innovative treatments for complex diseases is creating additional opportunities for clinical research and specialized service providers.
Germany is expected to register a 13.8% CAGR through 2036. Its developed healthcare infrastructure and established clinical research environment provide a strong foundation for cell and gene therapy development. Increasing focus on advanced treatment modalities and specialized clinical capabilities is supporting demand across the country’s market.
Competitive Landscape
The competitive environment includes companies such as IQVIA, ICON plc, Labcorp, Charles River Laboratories, and PAREXEL. These organizations participate across areas including clinical research, laboratory services, data management, regulatory support, and other activities required throughout the development lifecycle of advanced therapies.
As cell and gene therapy pipelines continue to expand, market participants are focusing on specialized capabilities that can address complex trial designs, regulatory requirements, patient recruitment, and operational challenges. Expansion into emerging markets and development of integrated clinical research services are also creating opportunities for companies operating across the value chain.
Outlook for the Cell and Gene Therapy Clinical Trials Market
The market is projected to add approximately USD 47.2 billion between 2026 and 2036. Rising investment in advanced therapy development, increasing clinical research activity, and the expansion of treatment applications are expected to remain important factors influencing future market performance. Stakeholders across biotechnology, pharmaceutical development, clinical research, and healthcare services can use the Fact.MR report to assess segment opportunities, country-level trends, competitive developments, and market forecasts.
Explore More Related Studies Published by Fact.MR Research
Wearable Infusion Adhesives Market
Smoke-Evacuating Trocars Market
About Fact.MR
Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.
– Contact Us –
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | [email protected]
